Skip to main content

Reductions in risk factors for secondary prevention of coronary heart disease

The UK health care system provides universal coverage; hence, equitable health improvement across ethnic groups should be more easily attainable than in fragmented health systems. However, previous studies have shown ethnic health inequalities in cardiovascular disease prevalence, health outcomes and access to interventions and treatment in the UK. In a recent paper published in Family Practice, Joanna Murray and colleagues examined whether policy changes over the past decade in the primary care management of coronary heart disease (CHD), have resulted in improved and more equitable risk factor control among patients. The study was carried out in Wandsworth in South-West London.

They found that over a 10-year period from 1998 to 2007, mean blood pressure among patients with CHD decreased from 140/80 to 133/74 mm Hg, while their mean cholesterol was reduced from 5.2 to 4.3 mmol/l. Reductions in these risk factors occurred among both males and females and across all ethnic groups. The findings from this study illustrate how a national health care system with universal coverage can significantly improve care for all ethnic groups in a major long-term illness, such as CHD. This is in contrast to more fragmented health care systems such as in the USA, where ethnic disparities remain more marked than in the UK. Further reducing inequalities in chronic disease management should remain a priority for primary care in the UK.


Popular posts from this blog

Improving discharge planning in NHS hospitals

Factors that need to be considered in discharge planning that have been identified in previous projects include:

Ensuring that discharge arrangements are discussed with patients, family members and carers; and that they are given a copy of the discharge summary.Adequate coordination between the hospital, community health services, general practices, and the providers of social care services.There is a follow-up after discharge of patients at high risk of complications or readmission - either in person or by telephone - to ensure that the discharge arrangements are working well. Medicines reconciliation is carried out. This is the process of verifying patient medication lists at a point-of-care transition, such as hospital discharge, to identify which medications have been added, discontinued, or changed from pre-admission medication lists.Ensuring that any outstanding test results at discharge are obtained and passed on to primary care teams; and ensuring there are clear arrangements …

Can GPs issue private prescriptions to NHS patients?

The NHS prescription charge in England is currently £8.40 per item. At this level, many commonly prescribed drugs will cost less than the prescription charge and so some NHS patients may occasionally ask if they can have a private prescription rather than an NHS prescription.

In the past, some GPs have been advised that they could issue both an NHS FP10 and a private prescription, and let the patient decide which to use. But the British Medical Association's General Practice Committee has obtained legal advice that said under the current primary care contract, GPs in England may not issue a private prescription alongside or as an alternative to an NHS FP10 prescription. In any consultation where a GP needs to issue an FP10, the concurrent issue of a private prescription would be a breach of NHS regulations.

The issuing of a private prescription in such circumstances could also be seen as an attempt to deprive the NHS of the funds it would receive from the prescription charge. Fur…

What impact will Brexit have on the UK's life sciences sector?

On Thursday 3 November 2016, I spoke at a seminar at the Imperial College Business School on the topic of the impact of Brexit on the UK's life sciences sector (the NHS, universities, and pharmaceutical and biomedical companies). I emphasised the important role played in the life sciences sector by EU-trained professionals and the need to ensure that the UK continued to attract highly-qualified professionals to work, for example, in our National Health Service. I also discussed the need to increase spending on research and development to ensure that the UK remained a world leader in the biomedical industry. The other speakers at the seminar were Andrew Lansley (former Secretary of State for Health) and Richard Phillips (Director of Healthcare Policy at the Association of British Healthcare industries). The event was chaired by Andrew Brown. A copy of my talk can be viewed on Slideshare.